Clinical Trial Update: Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating olaparib in metastatic renal cell carcinoma patients with DNA repair gene mutations is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Status: RECRUITING